A Phase 3 interventional study of Romosozumab and Placebo in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 10 sites in Korea, Republic of. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-10-07.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 7th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2017.
This study's enrollment of 67 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2017, is one of 14 in phase 3, and was the 22nd registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once a month for 6 months.
Drug: Placebo
Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
Drug: Romosozumab
Administered by subcutaneous injection once a month (QM)
Also known as: AMG 785, Evenity
Administered by subcutaneous injections once a month
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine
Bone mineral density (BMD) at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.
Time frame: Baseline and month 6
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip
Bone mineral density (BMD) at the total hip was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.
Time frame: Baseline and month 6
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck
Bone mineral density (BMD) at the femoral neck was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.
Time frame: Baseline and month 6
This study was conducted at 10 centers in South Korea. Participants were enrolled from 16 January 2017 to 17 August 2017.
| Milestone | Placebo | Romosozumab 210 mg |
|---|---|---|
| Started | 33 | 34 |
| Completed 6-month treatment period | 33 | 33 |
| Completed | 32 | 33 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Bone mineral density (BMD) at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine | -0.1 ± 0.8 | 9.5 ± 0.9 |
Bone mineral density (BMD) at the total hip was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip | 0.3 ± 0.4 | 2.9 ± 0.5 |
Bone mineral density (BMD) at the femoral neck was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck | 0.8 ± 0.7 | 3.0 ± 0.6 |
Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/33 (0%) | 2/33 (6.1%) | 4/33 (12.1%) |
| Romosozumab 210 mg | 0/34 (0%) | 0/34 (0%) | 2/34 (5.9%) |
| Event | Placebo | Romosozumab 210 mg |
|---|---|---|
| Pulmonary tuberculosisInfections and infestations | 1/33 | 0/34 |
| Femur fractureInjury, poisoning and procedural complications | 1/33 | 0/34 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 1/33 | 0/34 |
| Event | Placebo | Romosozumab 210 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 2/33 | 1/34 |
| Back painMusculoskeletal and connective tissue disorders | 2/33 | 1/34 |
| Age, Continuous(years) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | 68.4 ± 7.2 | 66.7 ± 7.6 | 67.5 ± 7.4 |
| Age, Customized(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| < 65 years | 13 | 14 | 27 |
| ≥ 65 to < 75 years | 13 | 16 | 29 |
| ≥ 75 years | 7 | 4 | 11 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Female | 33 | 34 | 67 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Asian | 33 | 34 | 67 |
| Lumbar Spine Bone Mineral Density (BMD) T-score(T-score) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | -2.6483 ± 0.6450 | -2.6622 ± 0.8155 | -2.6554 ± 0.7310 |
| Total Hip BMD T-score(T-score) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | -2.1797 ± 0.6243 | -2.1515 ± 0.7114 | -2.1654 ± 0.6650 |
| Femoral Neck BMD T-score(T-score) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | -2.5309 ± 0.5395 | -2.4494 ± 0.6069 | -2.4896 ± 0.5718 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Feb 2018, 12 months.
Results were first posted in Jul 2019, 1 year 4 months after primary completion. A results delay was requested in Dec 2018.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 12 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →